Research Summary

I direct a lab that focuses on genetic events that drive brain tumor formation and drug resistance and that in turn may serve as targets for the development of new therapies for brain tumors.

Research Funding

  • September 1, 2010 - August 31, 2025 - Training Program in Translational Brain Tumor Research , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: T32CA151022
  • December 1, 2005 - July 31, 2024 - Noninvasive Metabolic Signatures to Improve Management of Molecular Subtypes of Glioma , Co-Investigator . Sponsor: NIH, Sponsor Award ID: P01CA118816
  • September 20, 2002 - August 31, 2023 - Brain Tumor SPORE Grant , Co-Investigator . Sponsor: NIH, Sponsor Award ID: P50CA097257
  • September 15, 2017 - May 31, 2022 - Contributions of IDH1 mutation to alternative lengthening of telomeres in lower-grade glioma , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01NS105087
  • February 1, 2013 - January 31, 2019 - Understanding the role of altered metabolism in gliomagenesis , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA171610
  • July 1, 2009 - April 30, 2014 - A PTEN-regulated ubiquitin switch controlling TRAIL sensitivity in GBM , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA136774
  • June 1, 2006 - April 30, 2012 - UNDERSTANDING TRAIL SENSITIVITY IN HUMAN GLIOMA , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA115638
  • February 1, 2004 - January 31, 2010 - P38, G2 Arrest, and Temozolomide Resistance in Gliomas , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA100011
  • April 1, 2002 - March 31, 2007 - Contributions of Akt to Glioblastoma Formation , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA094989
  • July 1, 2000 - June 30, 2003 - TRIGGERING OF ABERRANT CPG ISLAND METHYLATION , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA085352
  • March 1, 1999 - February 28, 2002 - EXPRESSION AND SILENCING OF CPG ISLAND-CONTAINING GENES , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA079496
  • August 1, 1997 - June 30, 2000 - CHROMATIN STRUCTURE AND CONTROL , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA055064
  • July 1, 1994 - June 30, 1998 - ALKYLTRANSFERASE STRUCTURE AND FUNCTION , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA062389
  • July 1, 1991 - June 30, 1997 - ALKYLTRANSFERASE EXPRESSION/DNA METHYLATION , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R29CA055064
  • September 22, 1990 - January 1, 1900 - CONSEQUENCES OF SELECTIVE INDUCTION OF DNA CROSSLINKS , Principal Investigator . Sponsor: NIH, Sponsor Award ID: F32CA008685

Education

University of Wisconsin, Madison, WI, B.S., 1982, Pharmacy
George Washington Univ., Washington, D.C., Ph.D., 1987, Pharmacology

Selected Publications

  1. Schupp PG, Shelton SJ, Brody DJ, Eliscu R, Johnson BE, Mazor T, Kelley KW, Potts MB, McDermott MW, Huang EJ, Lim DA, Pieper RO, Berger MS, Costello JF, Phillips JJ, Oldham MC. Deconstructing intratumoral heterogeneity through multiomic and multiscale analysis of serial sections. bioRxiv. 2024 Mar 18.  View on PubMed
  2. Minami N, Hong D, Stevers N, Barger CJ, Radoul M, Hong C, Chen L, Kim Y, Batsios G, Gillespie AM, Pieper RO, Costello JF, Viswanath P, Ronen SM. Imaging biomarkers of TERT or GABPB1 silencing in TERT-positive glioblastoma. Neuro Oncol. 2022 11 02; 24(11):1898-1910.  View on PubMed
  3. Kumar A, Mohamed E, Tong S, Chen K, Mukherjee J, Lim Y, Wong CM, Boosalis Z, Shai A, Pieper RO, Gupta N, Perry A, Bollen AW, Molinaro AM, Solomon DA, Shieh JTC, Phillips JJ. CXCL14 Promotes a Robust Brain Tumor-Associated Immune Response in Glioma. Clin Cancer Res. 2022 07 01; 28(13):2898-2910.  View on PubMed
  4. Taglang C, Batsios G, Mukherjee J, Tran M, Gillespie AM, Hong D, Ronen SM, Artee Luchman H, Pieper RO, Viswanath P. Deuterium magnetic resonance spectroscopy enables noninvasive metabolic imaging of tumor burden and response to therapy in low-grade gliomas. Neuro Oncol. 2022 07 01; 24(7):1101-1112.  View on PubMed
  5. Tang Y, Mukherjee J, Pieper RO. MRE11 and UBR5 Co-Operate to Suppress RNF168-Mediated Fusion of Dysfunctional Telomeres. Front Oncol. 2021; 11:772233.  View on PubMed
  6. Viswanath P, Batsios G, Ayyappan V, Taglang C, Gillespie AM, Larson PEZ, Luchman HA, Costello JF, Pieper RO, Ronen SM. Metabolic imaging detects elevated glucose flux through the pentose phosphate pathway associated with TERT expression in low-grade gliomas. Neuro Oncol. 2021 09 01; 23(9):1509-1522.  View on PubMed
  7. Mukherjee J, Pandita A, Kamalakar C, Johannessen TC, Ohba S, Tang Y, Dalle-Ore CL, Bjerkvig R, Pieper RO. RETRACTED: A subset of PARP inhibitors induces lethal telomere fusion in ALT-dependent tumor cells. Sci Transl Med. 2021 05 05; 13(592).  View on PubMed
  8. Radoul M, Hong D, Gillespie AM, Najac C, Viswanath P, Pieper RO, Costello JF, Luchman HA, Ronen SM. Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma. Metabolites. 2021 Feb 13; 11(2).  View on PubMed
  9. Viswanath P, Batsios G, Mukherjee J, Gillespie AM, Larson PEZ, Luchman HA, Phillips JJ, Costello JF, Pieper RO, Ronen SM. Non-invasive assessment of telomere maintenance mechanisms in brain tumors. Nat Commun. 2021 01 04; 12(1):92.  View on PubMed
  10. Subramani E, Radoul M, Najac C, Batsios G, Molloy AR, Hong D, Gillespie AM, Santos RD, Viswanath P, Costello JF, Pieper RO, Ronen SM. Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment. Cancer Res. 2020 11 15; 80(22):5098-5108.  View on PubMed
  11. Ohba S, Murayama K, Kuwahara K, Pareira ES, Nakae S, Nishiyama Y, Adachi K, Yamada S, Sasaki H, Yamamoto N, Abe M, Mukherjee J, Hasegawa M, Pieper RO, Hirose Y. The Correlation of Fluorescence of Protoporphyrinogen IX and Status of Isocitrate Dehydrogenase in Gliomas. Neurosurgery. 2020 08 01; 87(2):408-417.  View on PubMed
  12. Jones LE, Hilz S, Grimmer MR, Mazor T, Najac C, Mukherjee J, McKinney A, Chow T, Pieper RO, Ronen SM, Chang SM, Phillips JJ, Costello JF. Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant glioma. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa088.  View on PubMed
  13. Molloy AR, Najac C, Viswanath P, Lakhani A, Subramani E, Batsios G, Radoul M, Gillespie AM, Pieper RO, Ronen SM. MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma. Theranostics. 2020; 10(19):8757-8770.  View on PubMed
  14. Ohba S, Johannessen TA, Chatla K, Yang X, Pieper RO, Mukherjee J. Phosphoglycerate Mutase 1 Activates DNA Damage Repair via Regulation of WIP1 Activity. Cell Rep. 2020 04 14; 31(2):107518.  View on PubMed
  15. Batsios G, Viswanath P, Subramani E, Najac C, Gillespie AM, Santos RD, Molloy AR, Pieper RO, Ronen SM. PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival. Sci Rep. 2019 07 19; 9(1):10521.  View on PubMed
  16. Chen D, Xia S, Wang M, Lin R, Li Y, Mao H, Aguiar M, Famulare CA, Shih AH, Brennan CW, Gao X, Pan Y, Liu S, Fan J, Jin L, Song L, Zhou A, Mukherjee J, Pieper RO, Mishra A, Peng J, Arellano M, Blum WG, Lonial S, Boggon TJ, Levine RL, Chen J. Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer. Cancer Discov. 2019 06; 9(6):756-777.  View on PubMed
  17. Radoul M, Najac C, Viswanath P, Mukherjee J, Kelly M, Gillespie AM, Chaumeil MM, Eriksson P, Delos Santos R, Pieper RO, Ronen SM. HDAC inhibition in glioblastoma monitored by hyperpolarized 13 C MRSI. NMR Biomed. 2019 02; 32(2):e4044.  View on PubMed
  18. Wood MD, Mukherjee J, Pieper RO. Neurofibromin knockdown in glioma cell lines is associated with changes in cytokine and chemokine secretion in vitro. Sci Rep. 2018 04 11; 8(1):5805.  View on PubMed
  19. Viswanath P, Radoul M, Izquierdo-Garcia JL, Luchman HA, Gregory Cairncross J, Pieper RO, Phillips JJ, Ronen SM. Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner. Cancer Metab. 2018; 6:3.  View on PubMed
  20. Mukherjee J, Johannessen TC, Ohba S, Chow TT, Jones L, Pandita A, Pieper RO. Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma. Cancer Res. 2018 06 01; 78(11):2966-2977.  View on PubMed

Go to UCSF Profiles, powered by CTSI